Skip to main content

Pharvaris

Community Commitment

Pharvaris is committed to strong collaboration with patient organizations, as well as with experts in the bradykinin-mediated angioedema (AE-BK) community, and supports the work undertaken on behalf of those living with AE-BK.

resources

For more support and resources please visit:

We invite healthcare professionals and those living with hereditary angioedema (HAE) to explore Pharvaris’ deflateHAE where real stories and insights highlight what living with HAE can be like.

Living with bradykinin-mediated angioedema (AE-BK)

Living with AE-BK can mean living with attacks that are unpredictable in frequency, location, timing, duration, and severity, imposing significant burden on emotional and physical wellbeing. AE-BK can affect all genders, ages, and ethnic groups.

Due to its rarity and overlap of symptoms with other conditions, AE-BK can be frequently under-recognized and/or misdiagnosed, especially in cases without family history.

How common is bradykinin-mediated angioedema?

HAE is a rare disease that is estimated to impact approximately 1 in 50,000 people:

USA ~7,000

Europe ~15,000

Acquired angioedema due to C1INH deficiency (AAE-C1INH) is an ultra-rare disease that is estimated to impact approximately 1 in 500,000 people:

USA ~700 people

Europe ~1,500 people
References

1. Banerji A, et al. Ann Allergy Asthma Immunol. 2020; 2. Betschel S, et al. Allergy Asthma Clin Immunol. 2019; 3. Bork K, et al. Am J Gastroenterol. 2006; 4. Bork K, et al. Am J Med. 2006; 5. Busse P and Kaplan A. J Allergy Clin Immunol Pract. 2022; 6. Caballero T, et al. J Investig Allergol Clin Immunol. 2016; 7. de Lange M, et al. J Allergy Clin Immunol. 2025; 8. Farkas H, et al. Allergy. 2017; 9. Food and Drug Administration. "The Voice of the Patient." 2017; 10. Frank MM, et al. Immunol Allergy Clin North Am. 2006; 11. Huang SW. Allergy Asthma Proc. 2004; 12. Johnston DT and Smith RC. Allergy Asthma Proc. 2020; 13. Lo SH, et al. Pharmacoecon Open. 2022; 14. Longhurst HJ and Bork K. Br J Hosp Med (Lond). 2019; 15. Longhurst H and Bygum A. Clin Rev Allergy Immunol. 2016; 16. Longhurst H and Cicardi M. Lancet. 2012; 17. Lumry WR, et al. Allergy Asthma Proc. 2010; 18. Lumry WR. Am J Manag Care. 2013; 19. Lumry WR and Settipane RA. Allergy Asthma Proc. 2020; 20. Magerl M, at al. Clin Transl Allergy. 2023; 21. Maurer M, et al. Allergy. 2022; 22. Mendivil J, et al. Orphanet J Rare Dis. 2021; 23. Pagnier A, et al. Pediatr Allergy Immunol. 2024; 24. Riedl MA, et al. Allergy Asthma Proc. 2021; 25. Riedl MA, et al. J Allergy Clin Immunol Pract. 2023; 26. Savarese L, et al. Allergy Asthma Proc. 2021; 27. Sylvestre S, et al. J Allergy Clin Immunol Pract. 2021; 28. Vazquez DO, et al. World Allergy Organ J. 2026; 29. Zanichelli A, et al. Ann Allergy Asthma Immunol. 2016; 30. Zotter Z, et al. Orphanet J Rare Dis. 2014; 31. Zuraw BL, et al. Clin Rev Allergy Immunology. 2025.